Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 158, P. 114204 - 114204

Published: Jan. 4, 2023

Glioblastoma (GBM) is one of the most malignant cancers central nervous system and due to its sensitive location, surgical resection has high risk therefore, chemotherapy radiotherapy are utilized for treatment. However, chemoresistance radio-resistance other problems in GBM Hence, new therapies based on genes recommended treatment GBM. PTEN a tumor-suppressor operator cancer that inhibits PI3K/Akt/mTOR axis diminishing growth, metastasis drug resistance. In current review, function PTEN/PI3K/Akt progression evaluated. Mutation or depletion leads increase progression. Low expression level mediates poor prognosis by increasing proliferation invasion, promotes malignancy tumor cells. Moreover, loss signaling can result therapy resistance Activation impairs metabolism via glycolysis inhibition. contrast PTEN, PI3K/Akt oncogenic during progression, enhances. shows positive association with pathways similar signaling, regulated non-coding RNAs. upregulation inhibition anti-cancer agents be beneficial interfering This review emphasizes networks related provides insights targeting this effective

Language: Английский

---

Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 160, P. 114392 - 114392

Published: Feb. 15, 2023

Prostate cancer is among most malignant tumors around the world and this urological tumor can be developed as result of genomic mutations their accumulation during progression towards advanced stage. Due to lack specific symptoms in early stages prostate cancer, patients are diagnosed that cells display low response chemotherapy. Furthermore, enhance aggressiveness cells. Docetaxel paclitaxel suggested well-known compounds for chemotherapy they possess a similar function therapy based on inhibiting depolymerization microtubules, impairing balance microtubules subsequent delay cell cycle progression. The aim current review highlight mechanisms docetaxel resistance cancer. When oncogenic factors such CD133 upregulation PTEN tumor-suppressor shows decrease expression, malignancy enhances induce drug resistance. phytochemicals anti-tumor have been utilized suppressing chemoresistance Naringenin lovastatin used enhancing sensitivity. Moreover, nanostructures polymeric micelles nanobubbles delivery decreasing risk development. These subjects highlighted provide new insight reversing

Language: Английский

---

Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response

Medicinal Research Reviews, Journal Year: 2023, Volume and Issue: 43(5), P. 1263 - 1321

Published: March 23, 2023

Abstract Gastrointestinal (GI) tumors (cancers of the esophagus, gastric, liver, pancreas, colon, and rectum) contribute to a large number deaths worldwide. STAT3 is an oncogenic transcription factor that promotes genes associated with proliferation, antiapoptosis, survival, metastasis. overactivated in many human malignancies including GI which accelerates tumor progression, metastasis, drug resistance. Research recent years demonstrated noncoding RNAs (ncRNAs) play major role regulation signaling pathways pathway. The types endogenous ncRNAs are being extensively studied oncology microRNAs, long RNAs, circular RNAs. These can either be tumor‐promoters or tumor‐suppressors each one them imparts their activity via different mechanisms. pathway also tightly modulated by ncRNAs. In this article, we have elaborated on tumor‐promoting tumors. Subsequently, comprehensively discussed as well suppressor functions mechanism action known modulate cancers.

Language: Английский

---

Molecular mechanisms behind ROS regulation in cancer: A balancing act between augmented tumorigenesis and cell apoptosis

Archives of Toxicology, Journal Year: 2022, Volume and Issue: 97(1), P. 103 - 120

Published: Nov. 28, 2022

Language: Английский

---

LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 154, P. 113609 - 113609

Published: Aug. 27, 2022

Epigenetic factors are critical regulators of biological and pathological mechanisms they could interact with different molecular pathways. Targeting epigenetic has been an idea approach in disease therapy, especially cancer. Accumulating evidence highlighted function long non-coding RNAs (lncRNAs) as cancer initiation development focused on their association downstream targets. microRNAs (miRNAs) the most well-known targets lncRNAs present review focuses lncRNA-miRNA axis malignancy therapy resistance tumors. LncRNA-miRNA regulates cell death such apoptosis autophagy cancers. This affects tumor metastasis via regulating EMT MMPs. Besides, determines sensitivity cells to chemotherapy, radiotherapy immunotherapy. Based studies, can be affected by drugs genetic tools this may affect expression level miRNAs targets, leading suppression/progression. LncRNAs have both tumor-promoting tumor-suppressor functions unique complicated implication therapy. also other signaling networks PI3K/Akt, STAT3, Wnt/β-catenin EZH2 among others. Notably, lncRNA/miRNA considered a signature for diagnosis prognosis

Language: Английский

---

Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs

Pharmacological Research, Journal Year: 2023, Volume and Issue: 194, P. 106775 - 106775

Published: April 17, 2023

Prostate carcinoma is a malignant situation that arises from genomic alterations in the prostate, leading to changes tumorigenesis. The NF-κB pathway modulates various biological mechanisms, including inflammation and immune responses. Dysregulation of promotes carcinogenesis, increased proliferation, invasion, therapy resistance. As an incurable disease globally, prostate cancer significant health concern, research into genetic mutations function has efficacy facilitate introduction novel therapies. upregulation observed during progression, resulting cell cycle progression proliferation rates. Additionally, endorses resistance death enhances capacity for metastasis, particularly bone metastasis. Overexpression triggers chemoresistance radio-resistance, inhibition by anti-tumor compounds can reduce progression. Interestingly, non-coding RNA transcripts regulate level its nuclear transfer, offering potential avenue modulating

Language: Английский

---

Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Aug. 27, 2024

Abstract The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, unique type regulated cell death, plays pivotal role inhibiting tumour growth, presenting new opportunities treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine vulnerability to ferroptosis. In this review, we first summarize the growth/development. Then, core molecular mechanisms ferroptosis, its upstream regulation, and downstream effects on Finally, review recent advances understanding how ncRNAs regulate ferroptosis from such modulate This aims enhance general ncRNA-mediated regulatory which highlighting ncRNA-ferroptosis axis as key druggable target overcoming

Language: Английский

---

The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 150, P. 113064 - 113064

Published: May 5, 2022

Clinically, cancer drug therapy is still dominated by chemotherapy drugs. Although the emergence of targeted drugs has greatly improved survival rate patients with advanced cancer, resistance always been a difficult problem in clinical treatment. At current level medicine, most cannot escape fate resistance. With and development gene detection, liquid biopsy ctDNA technology, single-cell sequencing molecular mechanism tumor gradually emerged. Drugs can also be updated response to mechanisms bring higher benefits. The use new often leads In this review, multi-molecular are introduced, overcoming discussed from perspective microenvironment.

Language: Английский

---

Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance

Pharmacological Research, Journal Year: 2022, Volume and Issue: 186, P. 106535 - 106535

Published: Nov. 2, 2022

Language: Английский

---

Targeting Autophagy Using Long Non-Coding RNAs (LncRNAs): New Landscapes in the Arena of Cancer Therapeutics

Cells, Journal Year: 2023, Volume and Issue: 12(5), P. 810 - 810

Published: March 6, 2023

Cancer has become a global health hazard accounting for 10 million deaths in the year 2020. Although different treatment approaches have increased patient overall survival, advanced stages still suffers from poor clinical outcomes. The ever-increasing prevalence of cancer led to reanalysis cellular and molecular events hope identify develop cure this multigenic disease. Autophagy, an evolutionary conserved catabolic process, eliminates protein aggregates damaged organelles maintain homeostasis. Accumulating evidence implicated deregulation autophagic pathways be associated with various hallmarks cancer. Autophagy exhibits both tumor-promoting suppressive effects based on tumor stage grades. Majorly, it maintains microenvironment homeostasis by promoting viability nutrient recycling under hypoxic nutrient-deprived conditions. Recent investigations discovered long non-coding RNAs (lncRNAs) as master regulators gene expression. lncRNAs, sequestering autophagy-related microRNAs, been known modulate cancer, such proliferation, EMT, migration, invasion, angiogenesis, metastasis. This review delineates mechanistic role lncRNAs involved modulating autophagy their related proteins cancers.

Language: Английский

---